Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

SML2419

Sigma-Aldrich

GSK690

≥98% (HPLC)

Sinonimo/i:

(R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl) benzonitrile), (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-p-tolylpyridin-3-yl)benzonitrile, 4-(2-(4-Methylphenyl)-5-((3R)-3-pyrrolidinylmethoxy)-3-pyridinyl)benzonitrile, GSK 354, GSK 690, GSK-354, GSK-690, GSK354

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C24H23N3O
Numero CAS:
2101305-84-2
Peso molecolare:
369.46
Codice UNSPSC:
12352200

Saggio

≥98% (HPLC)

Forma fisica

powder

Colore

white to beige

Solubilità

DMSO: 2 mg/mL, clear

Temperatura di conservazione

2-8°C

Stringa SMILE

N#CC1=CC=C(C2=CC(OC[C@H]3CNCC3)=CN=C2C4=CC=C(C)C=C4)C=C1

Azioni biochim/fisiol

GSK690 (GSK354) is a cell-permeable pyrrolidinylmethoxypyridine-based compound that inhibits lysine-specific demethylase 1 (LSD1; KDM1A) in a potent and reversible manner (IC50 = 90 nM) without affecting MAO-A activity (IC50 >200 μM). GSK690 is shown to induce the expressions of CD86 (EC50 = 1.4 μM in THP1 cells) and LY96 (EC50 = 423 nM in MV4-11 cells), and prevent adipogenesis in murine preadipocyte cultures.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Tinka Haydn et al.
Cell death & disease, 8(6), e2879-e2879 (2017-06-16)
The lysine-specific demethylase 1 (LSD1) is overexpressed in several cancers including rhabdomyosarcoma (RMS). However, little is yet known about whether or not LSD1 may serve as therapeutic target in RMS. We therefore investigated the potential of LSD1 inhibitors alone or
Alba Maiques-Diaz et al.
Cell reports, 22(13), 3641-3659 (2018-03-29)
Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid leukemia (AML) with MLL translocations. The assumption has been that differentiation is induced through blockade of LSD1's histone demethylase activity. However, we observed that rapid, extensive, drug-induced changes in transcription occurred
Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments
Hitchin JR, Blagg J, Burke R .
Medicinal Chemistry, 1513-1522 (2013)
Daniel P Mould et al.
Journal of medicinal chemistry, 60(19), 7984-7999 (2017-09-12)
Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukemia (AML). Irreversible inhibitors developed from the nonspecific inhibitor tranylcypromine have entered clinical trials; however, the development of effective
John P McGrath et al.
Cancer research, 76(7), 1975-1988 (2016-02-04)
Lysine-specific demethylase 1 (KDM1A) is a transcriptional coregulator that can function in both the activation and repression of gene expression, depending upon context. KDM1A plays an important role in hematopoiesis and was identified as a dependency factor in leukemia stem
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.